About Parion
Parion Sciences is a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The primary focus is in pulmonary indications including cystic fibrosis, COPD, and bronchiectasis. Parion Science’s technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC).
Therapeutic uses of topical ENaC blockers, including diseases of the lung, mouth, nose, and the gastrointestinal tract, have been identified and are in early stage development.